Exhibit 10.2

LICENSE AND RESEARCH AGREEMENT

AMENDMENT NO. 1

This License and Research Agreement Amendment No. 1 (this “Amendment No. 1”) is
made effective as of October 20, 2017 (the “Amendment Effective Date”) by and
between AIS Operating Co., Inc., f/k/a Alpine Immune Sciences, Inc., a Delaware
corporation (“Alpine”), and Kite Pharma, Inc., a Delaware corporation (“Kite”),
with reference to the following facts:

RECITALS

WHEREAS: Alpine and Kite entered into that certain License and Research
Agreement, effective as of October 26, 2015 (the “Agreement”), pursuant to
which, among other things, Alpine agreed to perform certain research services
and further agreed to grant Kite certain licenses under technology and
intellectual property rights controlled by Alpine and, in exchange for such
services and licenses, Kite agreed to pay certain research support and license
fees to Alpine, all as further described in the Agreement;

WHEREAS: Following the execution of the Agreement, effective as of July 24,
2017, Alpine changed its name from Alpine Immune Sciences, Inc. to AIS Operating
Co., Inc. as part of a business combination with what was then known as Nivalis
Therapeutics, Inc. and Nautilus Merger Sub, Inc.;

WHEREAS: Pursuant to Section 13.13 of the Agreement, the Agreement may be
amended by a writing signed by Alpine and Kite which specifies the provisions of
the Agreement that are thereby amended; and

WHEREAS: Alpine and Kite now desire to amend the Agreement to, among other
things, extend the Research Term, update the Research Plan, and modify the
payment terms for certain research support fees, all according to the terms, but
subject to the conditions and limitations set forth in this Amendment No. 1.

AMENDMENT

NOW, THEREFORE, in consideration of the foregoing and the agreements set forth
below, and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, Alpine and Kite (each a “Party” and together the
“Parties”) hereby agree as follows:

1. The recitals set forth above constitute an integral part of this Amendment
No. 1 and are incorporated herein by this reference with the same force and
effect as if set forth herein as agreements of the Parties.

 

[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

--------------------------------------------------------------------------------

2. Effective as of the Amendment Effective Date, Section 1.67 of the Agreement
is hereby amended by deleting such section in its entirety and inserting the
following in lieu thereof:

“1.67 “Research Term” means the period beginning on the Effective Date and
ending on the earlier to occur of the following: [****]

3. Effective as of the Amendment Effective Date, Section 3.1(a) of the Agreement
(Research Support) is hereby amended by deleting such section in its entirety
and inserting the following in lieu thereof:

“(a) Research Support. Kite shall pay Alpine research support totaling Nine
Hundred Thousand Dollars ($900,000) during the Term. The first (1st) installment
of Four Hundred Fifty Thousand Dollars ($450,000) shall be due within thirty
(30) days after the Effective Date. The second (2nd) installment of One Hundred
Fifty Thousand Dollars ($150,000) shall be due [****]. The third (3rd) and final
installment of Three Hundred Thousand Dollars ($300,000) shall be due [****].
The research support paid by Kite to Alpine under this Section 3.1(a) will be
noncreditable and nonrefundable. For clarity, each Party shall bear its own
costs and expenses in the performance of the Research Plan.”

4. Effective as of the Amendment Effective Date, the last sentence in
Section 4.1(a) of the Agreement (Overview) is hereby amended by deleting such
sentence in its entirety and inserting the following in lieu thereof:

“[****]”

5. Effective as of the Amendment Effective Date, Exhibit 4.1(b) of the Agreement
(Research Plan) is hereby amended by deleting such exhibit in its entirety and
inserting Schedule 1 attached hereto in lieu thereof.

6. Effective as of the Amendment Effective Date, the second sentence of
Section 4.2(a) of the Agreement (Conduct and Related Responsibilities) is hereby
amended by deleting such sentence in its entirety and inserting the following in
lieu thereof:

“Kite shall pay Alpine the research support fees pursuant to Section 3.1(a).”

7. Except as modified herein, all of the provisions of the Agreement shall
remain unchanged and in full force and effect. Capitalized terms used in this
Amendment No. 1 and not otherwise defined herein shall have the meanings
ascribed to such terms in the Agreement.

 

[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

--------------------------------------------------------------------------------

8. This Amendment No. 1 may be executed in counterparts, each of which shall be
an original, but all of which together shall be deemed to constitute one
(1) instrument.

[Signature Page Follows]

 

[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, this Amendment No. 1 is hereby executed as of the Amendment
Effective Date.

 

“ALPINE:”

AIS OPERATING CO., INC.,

f/k/a Alpine Immune Sciences, Inc.,

a Delaware corporation

By:

  /s/ Mitchell H. Gold, M.D.

Name: Mitchell H. Gold, M.D.

Its: Chief Executive Officer

 

Address:   201 Elliott Ave West   Suite 230   Seattle, WA 98119

 

“KITE:” KITE PHARMA, INC., a Delaware corporation

By:   /s/ David D. Chang, M.D., Ph.D.

Name:   David D. Chang, M.D., Ph.D.

Its:   EVP of R&D and CMO

 

[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

--------------------------------------------------------------------------------

SCHEDULE 1

Exhibit 4.1(b)

Research Plan

[****]

 

[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

--------------------------------------------------------------------------------

[****]

 

[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

--------------------------------------------------------------------------------

[****]

 

[****] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION